Anti Inflammatory Therapy Articles & Analysis
8 news found
LYR-210 is designed to be administered in a brief, non-invasive, in-office procedure and deliver up to six months of continuous anti-inflammatory medication to the sinonasal passages. "LYR-210 is the first product candidate designed to provide six months of continuous therapy with a single treatment and represents a significant opportunity to ...
"This release profile is exactly what I would want in an anti-inflammatory implant and the symptom improvement observed with LYR-210 is quite meaningful. ...
By delivering a consistent daily dose of the anti-inflammatory medication mometasone furoate directly to the sinonasal tissues continuously for six months, LYR-210 has shown robust CRS symptom improvement. ...
The pharmacokinetics and drug release study evaluated the release of mometasone furoate (MF), a potent anti-inflammatory corticosteroid formulated into Lyra’s proprietary XTreo™ matrix, in a rabbit model. ...
The company’s current pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy for months following a single non-invasive, in-office administration. ...
The company’s current pipeline of therapeutics target tissues deep in the ear, nose and throat passages and are designed to deliver continuous drug therapy for months following a single non-invasive, in-office administration. Lyra’s lead product candidate, LYR-210, is in late-stage clinical development for the treatment of chronic rhinosinusitis and is designed to ...
There have been numerous advancements in the world of cardiovascular therapeutics over the past decades, including development of intensive lipid-lowering agents such as PCSK9 inhibitors and anti-inflammatory therapies such as canakinumab. However, the promise of these therapeutics has yet to be fully realized because they are cost prohibitive ...
ByElucid
In addition to this neutralizing antibody development, Creative Biolabs’ antiviral drug discovery services also cover inhibitors of host cell protease (darunavir and lopinavir for SARS-CoV-2), viral protease inhibitors, nucleoside analogue inhibitors, RNA synthesis inhibitors, antiviral peptide, broad-spectrum antiviral drugs, anti-inflammatory drugs, ...